Beryl Drugs Ltd vs Vaishali Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Beryl Drugs Ltd is ₹ 21.75 as of 05 May 15:30 . The P/E Ratio of Beryl Drugs Ltd changed from 14.1 on March 2021 to 18.5 on March 2025 . This represents a CAGR of 5.58% over 5 yearsThe P/E Ratio of Vaishali Pharma Ltd changed from 32.9 on March 2021 to 209.7 on March 2025 . This represents a CAGR of 44.84% over 5 years The Market Cap of Beryl Drugs Ltd changed from ₹ 3.35 crore on March 2021 to ₹ 10.68 crore on March 2025 . This represents a CAGR of 26.10% over 5 yearsThe Market Cap of Vaishali Pharma Ltd changed from ₹ 171.9 crore on March 2021 to ₹ 134.85 crore on March 2025 . This represents a CAGR of -4.74% over 5 years The Revenue of Beryl Drugs Ltd is ₹ 0 crore as of Jun '25 .The Revenue of Vaishali Pharma Ltd is ₹ 24.59 crore as of Jun '25 . The EBITDA of Beryl Drugs Ltd is ₹ 0 crore as of Jun '25 .The EBITDA of Vaishali Pharma Ltd is ₹ 2.21 crore as of Jun '25 . The Net Profit of Beryl Drugs Ltd is ₹ 0 crore as of Jun '25 .The Net Profit of Vaishali Pharma Ltd is ₹ 1.28 crore as of Jun '25 . The Dividend Payout of Beryl Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Vaishali Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Beryl Drugs Ltd

Beryl Drugs Limited was incorporated on August 24, 1993.
The Company acquired the running business of M/s Flora and Fauna Remedies Limited on December 15, 1993.
The Shares of Company were listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange. The Company thereafter has been engaged in the manufacture, sale, and export of branded, generic pharmaceutical formulations in India and internationally.
It offers I.V. fluids, and a range of small and large volume injectables.
It provides a range of eye/ear drops, veterinary products, and injections.

About Vaishali Pharma Ltd

Vaishali Pharma Limited was originally incorporated as a Private Limited Company with the name 'Vaishali Pharma Private Limited' on 25th, April 2008.
On July 01, 2008 the Company acquired the business of proprietorship concerns of its Promoter Mr. Atul Vasani viz.
M/s.
Vaishali Pharmachem through Business Assignment agreement.
Consequently, the business of said Proprietorship Firm merged into Vaishali Pharma Private Limited.

FAQs for the comparison of Beryl Drugs Ltd and Vaishali Pharma Ltd

Which company has a larger market capitalization, Beryl Drugs Ltd or Vaishali Pharma Ltd?

Market cap of Beryl Drugs Ltd is 11 Cr while Market cap of Vaishali Pharma Ltd is 100 Cr

What are the key factors driving the stock performance of Beryl Drugs Ltd and Vaishali Pharma Ltd?

The stock performance of Beryl Drugs Ltd and Vaishali Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Beryl Drugs Ltd and Vaishali Pharma Ltd?

As of May 5, 2026, the Beryl Drugs Ltd stock price is INR ₹21.75. On the other hand, Vaishali Pharma Ltd stock price is INR ₹7.73.

How do dividend payouts of Beryl Drugs Ltd and Vaishali Pharma Ltd compare?

To compare the dividend payouts of Beryl Drugs Ltd and Vaishali Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.